Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [913]

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in...

Dr Giulia Pasello - University of Padova, Padua, Italy

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC ( Dr Giulia Pasello - University of Padova, Padua, Italy )

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer ( Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA )

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive...

Dr Sacha Rothschild - University of Basel, Basel, Switzerland

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC ( Dr Sacha Rothschild - University of Basel, Basel, Switzerland )

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus...

Prof Nicolas Girard - Institut Curie, Paris, France

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )

Consolidation durvalumab after cCRT shows decreased disease progression in LS...

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC ( Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

SIOG 2024: Updates in radiation oncology

Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia

SIOG 2024: Updates in radiation oncology ( Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia )

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France

SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )

More from ecancer